Renal Dose Adjustment (Based on CrCl)
- 10-50 mL/min: Decrease dose by 50%
- < 10 mL/min: Avoid use
Hepatic Dose Adjustment
- Hepatic impairment: Dose adjustments not defined
- Terbutaline sulfate has not been approved and should not be used for prolonged tocolysis (beyond 48 - 72 hours). In particular, terbutaline sulfate should not be used for maintenance tocolysis in the outpatient or home setting [US black box warning]
- Serious adverse reactions, including death, have been reported after administration of terbutaline sulfate to pregnant women. In the mother, these adverse reactions include increased heart rate, transient hyperglycemia, hypokalemia, cardiac arrhythmias, pulmonary edema and myocardial ischemia. Increased fetal heart rate and neonatal hypoglycemia may occur as a result of maternal administration [US black box warning]
- Deterioration of asthma may occur. If patient need more doses of terbutaline than usual, reevalaute treatment regimen. Destabilization of asthma may require treatment with corticosteroids
- Beta-adrenergic agonist bronchodilators alone may not be adequate to control asthma. Incorporation of corticosteroids early in therapy is recommended
- Acute hypersensitivity reactions and exacerbation of bronchospasm have been reported after terbutaline administration
- Safety and efficacy in children younger than 12 yr of age not established
Cautions: Use cautiously in
- Cardiovascular disease
- Hypertension
- CAD
- Cardiac arrhythmias
- Diabetes mellitus
- Hyperthyroidism
- History of seizure disorder
- Pregnancy
- Lactation
Pregnancy Category:B
Breastfeeding: Probably safe.
